SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update
SCYNEXIS reported third-quarter 2026 financial results and corporate updates, including completion of a Phase 1 study of SCY-770 supporting its planned ADPKD Phase 2 program, a BARDA contract providing up to approximately $214 million in non-dilutive funding for SCY-247, and completion of an intravenous SCY-247 Phase 1 study.
Why it matters — The update highlights progress in two clinical programs and substantial potential non-dilutive funding for SCY-247.